Showing 20 of 132 recruiting trials for “precursor-t-cell-acute-lymphoblastic-leukemia”
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingNCT05840575 ↗
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Bright Ideas - CIN Feasibility Study
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
RecruitingNCT05014165 ↗
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
👨⚕️ Adam de Smith, PhD, University of Southern California Keck School of Medicine📍 1 site📅 Started Aug 2021View details ↗
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
👨⚕️ Jianxiang Wang, Dr., Institute of Hematology & Blood Diseases Hospital, China📍 11 sites📅 Started Dec 2020View details ↗
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
RecruitingNCT04290000 ↗
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
👨⚕️ Anna Halpern, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2020View details ↗
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
👨⚕️ Matthew J Wieduwilt, Alliance for Clinical Trials in Oncology📍 271 sites📅 Started May 2019View details ↗
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
👨⚕️ Mary-Elizabeth Percival, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Nov 2018View details ↗
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
👨⚕️ Prof. Dr. Michael Schmitt, University Hospital Heidelberg, Department V📍 2 sites📅 Started Sep 2018View details ↗
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →